Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ TOPORS Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5116849
Description
Positive Samples: Mouse liver, Mouse lung, Mouse kideny, Rat kidney Immunogen sequence: PDSKCPICLD RFDNVSYLDR CLHKFCFRCV QEWSKNKAEC PLCKQPFDSI FHSVRAEDDF KEYVLRPSYN GSFTNPEVRR FRYRTTMTRE RSASLYSPSS T.
Functions as an E3 ubiquitin-protein ligase and as an E3 SUMO1-protein ligase. Probable tumor suppressor involved in cell growth, cell proliferation and apoptosis that regulates p53/TP53 stability through ubiquitin-dependent degradation. May regulate chromatin modification through sumoylation of several chromatin modification-associated proteins. May be involved in DNA damage-induced cell death through IKBKE sumoylation.
Specifications
TOPORS | |
Polyclonal | |
Unconjugated | |
TOPORS | |
AW105885; E3 ubiquitin-protein ligase Topors; LUN; p53-binding protein 3; P53BP3; p53BP3/LUN; RING-type E3 ubiquitin transferase Topors; RP31; SUMO1-protein E3 ligase Topors; TOP1 binding arginine/serine rich protein; topoisomerase 1-binding RING finger; topoisomerase I binding, arginine/serine-rich; topoisomerase I binding, arginine/serine-rich, E3 ubiquitin protein ligase; topoisomerase I-binding arginine/serine-rich protein; Topoisomerase I-binding RING finger protein; Topors; TP53BPL; tumor suppressor p53-binding protein 3 | |
Rabbit | |
Affinity chromatography | |
RUO | |
106021, 362501 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
ELISA, Western Blot | |
1.4 mg/mL | |
PBS with 50% glycerol and 0.01% thimerosal; pH 7.3 | |
Q80Z37 | |
TOPORS | |
A synthetic peptide corresponding to a sequence within amino acids 100-200 of mouse Topors (NP_5988582). | |
100 μL | |
Primary | |
Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction